Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.56 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324835 | 1.00 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAPPARGPPARA | |
| SCHEMBL1318658 | 1.00 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAPPARGPPARA | |
| SCHEMBL24945914 | 0.94 | ACE (0.53) | FOLH1NAALAD2RIMKLAPPARGPPARA | |
| SCHEMBL8215506 | 0.94 | CTSS (0.51) | FOLH1NAALAD2RIMKLAPPARGPPARA | |
| SCHEMBL20081129 | 0.94 | ACE (0.53) | FOLH1NAALAD2RIMKLAPPARGPPARA | |
| Glutamic Acid SCHEMBL2482358 | 0.91 | GRM8 (0.51) | FOLH1NAALAD2RIMKLAPPARGPPARA | |
| SCHEMBL30853504 | 0.91 | PPARA (0.48) | FOLH1NAALAD2RIMKLAPPARGPPARA | |
| SCHEMBL3432850 | 0.90 | CTSK (0.51) | FOLH1NAALAD2RIMKLAPPARGPPARA | |
| SCHEMBL6036315 | 0.90 | CTSK (0.51) | FOLH1NAALAD2RIMKLAPPARGPPARA | |
| SCHEMBL3431559 | 0.90 | CTSK (0.51) | FOLH1NAALAD2RIMKLAPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111253464-B | Gamma-glutamyl transpeptidase targeted molecular probe and preparation method and application thereof | 江苏省原子医学研究所 | 2022-02-01 | — | — | CN | claimed |
| CN-113501947-A | Polyester with amino group and preparation method thereof | 温州医科大学 | 2021-10-15 | — | — | CN | claimed |
| CN-111253464-A | Gamma-glutamyl transpeptidase targeted molecular probe and preparation method and application thereof | 江苏省原子医学研究所 | 2020-06-09 | — | — | CN | claimed |
| CN-103724392-B | A kind of preparation method of amino acid phytosterol ester hydrochloride | JIANGNAN UNIVERSITY (CN) | 2016-03-02 | — | — | CN | claimed |
| CN-103724392-A | Preparation method of amino acid phytosterol ester hydrochloride | UNIV JIANGNAN | 2014-04-16 | — | — | CN | claimed |
| CN-101538242-B | Synthetic method of Benazepril key intermediate S-amino substance | UNIV ZHEJIANG TECHNOLOGY | 2011-05-25 | — | — | CN | claimed |
| CN-101538242-A | Synthetic method of Benazepril key intermediate S-amino substance | UNIV ZHEJIANG TECHNOLOGY | 2009-09-23 | — | — | CN | claimed |
| CN-1325389-A | 2-aminothiazole derivatives, process for preparing the same and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2001-12-05 | — | — | CN | claimed |
| US-4824974-A | Synthesis for the preparation of 4-amino-4,5-dihydro-2-furancarboxylic acid | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-04-25 | — | — | US | claimed |
| EP-4628481-A1 | COMPOUND AND USE THEREOF IN TREATMENT OF TREG-RELATED DISEASES | Benethera (Shaoxing) Biotechnology Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025134071-A1 | MALIC AND GLUTARIC ACID BASED IONIZABLE LIPIDS | SANOFI (FR) | 2025-06-26 | — | — | WO | disclosed |
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-13 | — | — | US | disclosed |
| US-20240228433-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2024-07-11 | — | — | US | disclosed |
| EP-0543997-A1 | NOVEL METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1993-06-02 | — | — | EP | disclosed |
| US-5068177-A | Immunology, diagnosis for immunoglobulins for autoimmune controllers | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0290211-B1 | DIHYDROPYRIDINES | Pfizer Limited (GB) | 1991-09-04 | — | — | EP | disclosed |
| US-4806557-A | Dihydropyridines and use thereof in treating hypertension and ischaemia | PFIZER INC. (US) | 1989-02-21 | — | — | US | disclosed |
| EP-0290211-A1 | Dihydropyridines | Pfizer Limited (GB) | 1988-11-09 | — | — | EP | disclosed |
| US-4415657-A | USING MICRORGANISMS FOR THE STEREOSPECIFIC HYDROGENOLYSIS OF THE DIALKYL B-PROTECTED AMINO ESTER | KANEGAFUCHI CHEMICAL INDUSTRY COMPANY, LIMITED (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | LGMN, BUB1B, KIF15 | FOLH1 671/4885NAALAD2 65/4885RIMKLA 2096/4885 |
| US-20240228433-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLRMT, POLR2E | FOLH1 1333/4885NAALAD2 3573/4885RIMKLA 2041/4885 |
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | FOLH1 1736/4885NAALAD2 2557/4885RIMKLA 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.